| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 6, 2025
Harmony™ Transcatheter Pulmonary Valve system approval expands minimally invasive treatment options for patients with congenital heart disease across European Union
-
Nov 26, 2024
Two data releases at London Valves 2024 build on Evolut’s legacy of valve design and performance: Optimize PRO study demonstrates improved procedure efficiencies and valve performance Pooled...
-
Nov 20, 2024
Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies
-
Oct 24, 2024
Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access
-
Jun 7, 2024
New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.